Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib for Anaplastic Thyroid Cancer (HOPE)
NCT02726503Phase 2Completed
- Sponsor
- Translational Research Center for Medical Innovation
- Start
- Apr 2016
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in anaplastic thyroid cancer (ATC), sponsored by Translational Research Center for Medical Innovation. Started Apr 2016; status: completed.
02
Drugs
lenvatinib
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT02726503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02726503.